Trial Profile

Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 03 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atorvastatin (Primary)
Indications Age-related macular degeneration; Choroidal neovascularisation; Dry macular degeneration
Focus Therapeutic Use
Acronyms DELPHI

Most Recent Events

26 Jan 2026 Planned End Date changed from 1 Jan 2024 to 1 Jan 2028.
26 Jan 2026 Planned primary completion date changed from 1 Jan 2023 to 1 Apr 2027.
07 Oct 2021 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com